ArticleFrontiers in medicine2026
Clinicopathological features and diagnostic challenges of hepatic epithelioid angiomyolipoma: a retrospective analysis of 27 cases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic epithelioid angiomyolipoma, a rare mesenchymal tumor, poses significant diagnostic challenges due to its rarity and non-specific presentation. Existing literature is dominated by case reports, limiting a systematic understanding of its clinicopathological profile. Therefore, further in-depth research is of great significance for elucidating the nature and clinical features of this disease. Objective: To define the clinicopathological characteristics, diagnostic features, and management outcomes of Hepatic epithelioid angiomyolipoma by analyzing a single-center cohort. Methods: We retrospectively analyzed 27 patients diagnosed with hepatic epithelioid angiomyolipoma at a single institution between April 2019 and November 2024. We collected and examined data on clinical presentation, laboratory findings, imaging results from ultrasound, computed tomography, and magnetic resonance imaging, as well as histopathological and immunohistochemical features. Results: The cohort was predominantly female (88.9%; 24/27), with a mean age of 44.2 years, and most patients (81.5%; 22/27) were asymptomatic. Preoperative imaging frequently mimicked other liver tumors, resulting in a correct preoperative diagnosis in only 3.7% of cases. Pathologically, all tumors tested were positive for HMB-45 (100%) and Melan-A (100%). Surgical resection was the primary treatment (96.3%). Tissue biopsy combined with microwave ablation was performed in 3.7% (1/27) of the patients. 27 cases were diagnosed as typical hepatic epithelioid angiomyolipoma. Conclusion: Hepatic epithelioid angiomyolipoma presents with non-specific clinical and radiological features, making preoperative diagnosis challenging and often leading to misdiagnosis as other common liver tumors. Definitive diagnosis depends on histopathological and immunohistochemical analysis. Surgical resection remains the primary treatment due to the tumor's malignant potential. A high index of suspicion and reliance on pathological confirmation are crucial for accurate management of this rare tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.